Tradestie Institutional Equity Comparison Engine

XBIO vs ACHV โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ACHV Overall Edge

ACHV Captures Institutional Edge (4โ€“0 Pillars ยท 8โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Achieve Life Sciences, Inc. (ACHV) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, XBIO trades at N/M Forward P/E with -81.0% operating margin (+12.0% YoY revenue) versus ACHV at 35.3x Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, XBIO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ACHV sits in BREAKOUT (23rd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner ACHV
XBIO N/M vs ACHV 35.3x Fwd P/E
Growth & Margin Winner ACHV
Op Margin -81.0% vs 0.0% ยท YoY +12.0% vs +0.0%
Momentum & Technical Winner ACHV
1Y -42.0% vs +43.0% ยท 52W Pos 2% vs 69%
Options & Structure Winner ACHV
UNCLASSIFIED (N/A IV) vs BREAKOUT (23rd %ile IV)
XBIO NASDAQ
Xenetic Biosciences, Inc.
Pharmaceutical Preparations
$1.49
-10.24% 1D
Market Cap $3.9M
1M Return -25.13%
1Y Return -42.02%
Forward P/E N/M
Unified AI Score
47.1 / 100 HOLD
Tech 33.0 Fund 50.0 Flow 50.0 Mom 74.0
ACHV NASDAQ
Achieve Life Sciences, Inc.
In Vitro & In Vivo Diagnostic Substances
$6.78
+0.89% 1D
Market Cap $692.8M
1M Return -8.5%
1Y Return +43.04%
Forward P/E 35.3x
Unified AI Score
56.6 / 100 HOLD
Tech 66.0 Fund 58.0 Flow 57.0 Mom 58.9

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: XBIO -42.02% ACHV +43.04% Spread: +78.09 pp (ACHV Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
XBIO TTM Op. Margin: -81.0% ACHV TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XBIO vs ACHV. Trailing 12-month operating profitability (XBIO -81.0% vs ACHV 0.0%) and valuation multiples (XBIO N/M vs ACHV 35.3x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: XBIO (2) vs ACHV (8)
Institutional Metric XBIO ACHV Criterion Row Winner
Market Capitalization Scale $3.9M $692.8M Larger Scale ACHV
Trailing P/E Ratio Valuation N/M 35.3x Lower Multiple ACHV
Forward P/E Ratio Valuation N/M 35.3x Lower Multiple ACHV
Revenue Growth (YoY) Growth +12.0% +0.0% Higher Growth XBIO
Operating Margin (TTM) Profitability -81.0% 0.0% Higher Margin ACHV
Net Profit Margin Profitability -75.9% 0.0% Higher Margin ACHV
Return on Equity (ROE) Capital Efficiency -47.0% -845.0% Higher ROE XBIO
52-Week Range Position Momentum 2% ($1โ€“$5) 69% ($3โ€“$9) Stronger Trend ACHV
Beta / 30D Volatility Risk Regime 1.60ฮฒ ยท 97% Vol 1.73ฮฒ ยท 62% Vol Lower Realized Risk ACHV
Unified Institutional Score Composite Signal 47.1 / 100 (HOLD) 56.6 / 100 (HOLD) Higher Composite ACHV

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full XBIO vs ACHV Buy Guide
XBIO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live XBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ACHV BREAKOUT
125d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 23rd %ile
IV Regime Compressed (<25th %ile)
Live ACHV Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither XBIO nor ACHV registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.